072020.KQ Choong Ang Vaccine Laboratory Co. Ltd
- Market cap
- KRW 81.6B
- P/E
- 22.5x
- P/B
- 0.75x
- ROE
- 8.6%
- Dividend yield
- 1.99%
- Fundamental score
- 3.4/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 072020.KQ undervalued?
Graham number072020.KQ trades 13.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Choong Ang Vaccine Laboratory Co. Ltd fundamental analysis
16 of 22 checks passedROE 0/2
Low return on equity (8.6%), below 10%.
ROA 1/1
Return on assets (7.4%) is above the industry median (1.4%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-7.2%) is not above the 5-year average (15.7% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-7.2%) is below the industry median (1.8%).
Revenue Growth 1/2
Revenue grew 7.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (3.7%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 55.0x against interest expense, well covered.
PE vs Market 0/1
PE (22.5x) is above the market median (11.3x).
PE vs Industry 0/1
PE (22.5x) is above the industry median (11.4x).
PBV 1/1
Price to book (0.8x) is below the industry median (0.9x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 17.0, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 1.43, above 1.
Dividend Yield 1/2
Dividend yield (2.0%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 11 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 26.4%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Choong Ang Vaccine Laboratory Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Choong Ang Vaccine Laboratory Co. Ltd
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Korea.
Full company profileChoong Ang Vaccine Laboratory Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Choong Ang Vaccine Laboratory Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 37.9B | 31.9B | 33.2B | 32.9B | 36.3B | 40.9B | 39.3B | 41.9B | 45.6B | 49.1B | 49.0B |
| Gross Profit | 16.9B | 15.1B | 13.7B | 14.0B | 16.8B | 19.0B | 18.8B | 21.5B | 21.3B | 23.9B | 25.5B |
| Operating Income | 6.94B | 5.55B | 3.50B | 2.71B | 4.03B | 4.54B | 4.28B | 6.97B | 5.76B | 6.48B | 8.28B |
| EBITDA | - | - | - | - | - | - | 11.1B | 13.3B | 13.7B | 13.1B | 16.9B |
| Net Income | 6.21B | 4.58B | 3.45B | 1.85B | 3.16B | 7.60B | 4.04B | 6.00B | 6.85B | 6.16B | 9.24B |
| EPS | 684 | 505 | 347 | 186 | 321 | 779 | 418 | 621 | 717 | 665 | 999 |
| Balance Sheet | |||||||||||
| Total Assets | 73.5B | 81.6B | 96.7B | 96.6B | 105B | 113B | 115B | 120B | 123B | 123B | 126B |
| Total Liabilities | 13.2B | 16.9B | 11.7B | 10.2B | 17.4B | 20.0B | 19.6B | 19.8B | 19.4B | 17.4B | 17.4B |
| Shareholders' Equity | 60.4B | 64.7B | 85.0B | 86.4B | 87.5B | 93.0B | 95.3B | 99.8B | 104B | 105B | 108B |
| Cash & Short-term Investments | 20.1B | 15.0B | 28.3B | 24.3B | 22.8B | 21.5B | 18.0B | 27.4B | 29.2B | 10.5B | 14.1B |
| Total Debt | 6.59B | 8.50B | 5.40B | 4.16B | 10.1B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.71B | 7.56B | 5.71B | 8.30B | 8.32B | 11.5B | 7.09B | 12.7B | 13.4B | 7.87B | 16.0B |
| Capital Expenditure | 7.22B | 13.2B | 5.89B | 6.71B | 15.4B | 14.3B | 7.10B | 1.92B | 7.17B | 5.98B | 5.26B |
| Free Cash Flow | - | - | - | - | -7.09B | -2.84B | -83.8M | 10.8B | 6.23B | 1.90B | 10.7B |
| Ratios | |||||||||||
| ROE | 10.3% | 7.1% | 4.1% | 2.1% | 3.6% | 8.2% | 4.2% | 6.0% | 6.6% | 5.8% | 8.6% |
| ROA | 8.4% | 5.6% | 3.6% | 1.9% | 3.0% | 6.7% | 3.5% | 5.0% | 5.6% | 5.0% | 7.4% |
| Net Profit Margin | 16.4% | 14.4% | 10.4% | 5.6% | 8.7% | 18.6% | 10.3% | 14.3% | 15.0% | 12.5% | 18.9% |
| Debt to Equity | 0.11x | 0.13x | 0.06x | 0.05x | 0.12x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Choong Ang Vaccine Laboratory Co. Ltd dividends
- Dividend yield
- 1.99%
- Forward dividend
- 200.00 KRW
- Payout ratio
- 26.4%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 1.62B | 176 | 26.4% |
| 2024 | KRW 1.45B | 152 | 21.2% |
| 2023 | KRW 967M | 100 | 16.1% |
| 2022 | KRW 976M | 101 | 24.1% |
| 2021 | KRW 690M | 71 | 9.1% |
| 2020 | KRW 498M | 51 | 15.7% |
| 2019 | KRW 498M | 50 | 26.9% |
| 2018 | KRW 366M | 37 | 10.6% |
| 2017 | KRW 366M | 40 | 8.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jul 18, 2018.
Who owns Choong Ang Vaccine Laboratory Co. Ltd
- Insiders 36.47%
- Institutions 0.41%
- Public & others 63.13%
- Shares outstanding 9.26M
- Free float 6.14M
Choong Ang Vaccine Laboratory Co. Ltd company profile
- Company name
- Choong Ang Vaccine Laboratory Co. Ltd
- Ticker
- 072020.KQ
- ISIN
- KR7072020001
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 167
- Fiscal year end
- December
- Address
- 1476-37 Yuseong-daero, Daejeon, South Korea, 34055
- Phone
- 82 4 2863 9322
- Website
- cavac.co.kr
About Choong Ang Vaccine Laboratory Co. Ltd
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Korea.
Choong Ang Vaccine Laboratory Co. Ltd management
1- Mr. In-Joong YoonChief Executive Officer & Chairman · born 1962